ProBioGen has expanded both protein and virus manufacturing at its Berlin headquarters—including the commissioning of an additional 1000L-scale GMP production line for proteins and the completion of the construction phase of its virus manufacturing unit.

“These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer’s needs,” explains Dr. Alfred Merz, Chief Executive Officer at ProBioGen.

In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen’s ability to support partners from cell line development through to commercial manufacturing. Utilizing its CHO.RiGHT platform in combination with market-approved technologies such as the DirectedLuck transposase and the ADCC enhancement GlymaxX, ProBioGen reinforces its position as a reliable partner in the industry. With this investment, the company strengthens its footprint in the market and is advancing its facilities across two manufacturing sites.

In the viral vector arena, ProBioGen is building on a broad experience in developing proprietary viral manufacturing platforms to offer solutions that go beyond standard processes. The company provides tailored cell lines for producing viral vectors and virus-like particles (VLPs). This includes customized stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) production, addressing the unique challenges of emerging therapeutic platforms and enabling the creation of next-generation therapies with precision and efficiency.

More ProBioGen News

In November, Transgene, a biotech company, and ProBioGen entered into a license agreement for ProBioGen’s AGE1.CR.pIX suspension cell line.